Canaccord analyst Richard Close raised the firm’s price target on Doximity (DOCS) to $67 from $59 and keeps a Hold rating on the shares. The firm met with managment and discussed Doximity’s AI clinical reference acquisition of Pathway and its longer-term AI opportunity. The company’s growing technology tool set should continue to drive increasing clinician engagement. As a result, demand for the company’s marketing and brand awareness solutions should grow as Pharma marketing increasingly shifts to digital formats.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Doximity price target raised to $80 from $75 at Baird
- Doximity could be impacted by FDA ad crackdown, says Raymond James
- Doximity Holds Annual Stockholders Meeting, Elects Directors
- Doximity Announces Leadership Change with New Appointments
- Doximity’s Strong Market Position and AI-Driven Growth Reinforce Buy Rating